https://scholars.lib.ntu.edu.tw/handle/123456789/633131
標題: | Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion | 作者: | Papatheodoridis, George V. Lekakis, Vasileios Voulgaris, Thodoris Lampertico, Pietro Berg, Thomas Chan, Henry L.Y. JIA-HORNG KAO Terrault, Norah Lok, Anna S. Reddy, K. Rajender |
關鍵字: | Antiviral prophylaxis | Biologics | Chemotherapy | Hepatitis flares | Immunotherapy | 公開日期: | 1-十二月-2022 | 卷: | 77 | 期: | 6 | 來源出版物: | Journal of Hepatology | 摘要: | HBV reactivation (HBVr) can be prevented by nucleos(t)ide analogues (NAs). We conducted a systematic review and meta-analysis on the risk of HBVr associated with new classes of immunosuppressive and immunomodulatory therapies and developed guidance on NA prophylaxis. An expert panel reviewed the data and categorised the risk of HBVr associated with each class of drugs into low (<1%), intermediate (1-10%), and high (>10%). Our search uncovered 59 studies, including 3,424 HBsAg+ and 5,799 HBsAg-/anti-HBc+ patients, which met our eligibility criteria. Based on medium-high quality evidence, immune checkpoint inhibitors, tyrosine kinase inhibitors, cytokine inhibitors, chimeric antigen receptor T-cell immunotherapies, and corticosteroids were associated with high HBVr risk in HBsAg+ patients; cytokine inhibitors, chimeric antigen receptor T-cell immunotherapies, and corticosteroids with intermediate risk in HBsAg-/anti-HBc+ patients; and anti-tumour necrosis factor agents and immune checkpoint inhibitors with low risk in HBsAg-/anti-HBc+ patients. Provisional recommendations are provided for drugs with low quality evidence. NA prophylaxis is recommended when using drugs associated with a high HBVr risk, while monitoring with on-demand NAs is recommended for low-risk drugs – either approach may be appropriate for intermediate-risk drugs. Consensus on definitions and methods of reporting HBVr, along with inclusion of HBsAg+, and HBsAg-/anti-HBc+ patients in clinical trials, will be key to gathering reliable data on the risk of HBVr associated with immunosuppressive or immunomodulatory therapies. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633131 | ISSN: | 01688278 | DOI: | 10.1016/j.jhep.2022.07.003 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。